FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

K.S.A. 65-1657(a) says no nonresident pharmacy may ship, mail or deliver prescription drugs or devices 'to a patient, patient's agent or prescriber's office' in Kansas unless registered as a nonresident pharmacy. Registration renews every year. Under K.S.A. 65-1657(b), the pharmacy must disclose its owners and officers and the names of all pharmacists dispensing to Kansas residents, and must be registered and in good standing in its home state. It must keep records of Kansas prescriptions and provide a toll-free line for Kansas patients to consult a pharmacist. K.A.R. 68-7-12a requires a designated pharmacist-in-charge licensed in the state where they practice; a Kansas license is not required by the rule text. The same rule requires a record of a satisfactory inspection within the previous 18 months, by the home-state licensing entity or a third party recognized by the Board. The Kansas Board of Pharmacy enforces these rules.

K.S.A. 65-1657 was last amended by L. 2021, ch. 106. K.A.R. 68-7-12a was last amended effective 2018-01-12, which is older than two years; Cornell showed it as current on 2026-09-23. The Board website (pharmacy.ks.gov) blocked automated access, so its current application checklist was not checked. Kansas's sterile and non-sterile compounding rules (K.A.R. 68-13-3, 68-13-4) define 'pharmacy' to include nonresident pharmacies. No separate nonresident sterile-compounding permit was found.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

K.A.R. 68-13-4(m) (sterile) and K.A.R. 68-13-3 (non-sterile) say any pharmacy may distribute compounded preparations without a prescription. This includes limited quantities given to a practitioner in the course of professional practice to administer to an individual patient, as long as the preparations are not intended for resale. K.A.R. 68-13-4(l) and 68-13-3 require these to be labeled 'For Office Use Only - Not For Resale.' K.A.R. 68-13-4(b)(5) defines 'pharmacy' to include nonresident pharmacies and outsourcing facilities. K.S.A. 65-1657(a) likewise contemplates nonresident pharmacies shipping to a 'prescriber's office.' No numeric quantity cap is set. FDA's position is that 503A needs patient-specific prescriptions, so this state allowance goes further than the federal view. The Kansas Board of Pharmacy enforces these rules.

K.A.R. 68-13-3 and 68-13-4 took effect 2018-05-11 (Kan. Reg. Vol. 37, No. 17). That is older than two years and possibly stale if the Board has updated its compounding rules for USP <797> (2023); Cornell showed this text as current on 2026-09-23. The exact subsection letters in K.A.R. 68-13-3 were not captured. The Board website blocked automated access.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

K.S.A. 65-1643(n) makes it unlawful to 'operate as an outsourcing facility outside of Kansas and ship, mail or deliver drugs into this state' without first registering with the Board. K.S.A. 65-1626(vv) defines an outsourcing facility as a facility at one location that compounds sterile drugs and is registered with FDA under 21 U.S.C. §353b. A separate provision, K.S.A. 65-1643(p), requires out-of-state manufacturers to register as manufacturers. K.A.R. 68-13-4 defines 'pharmacy' to include outsourcing facilities for Kansas's sterile-preparation standards. The Kansas Board of Pharmacy enforces these rules.

The lead citation 'K.S.A. 65-1676' was not used; the outsourcing registration requirement is in K.S.A. 65-1643(n), last amended by L. 2021, ch. 106. The Board website blocked automated access, so application details were not checked, including any FDA-inspection report or designated-representative requirement for nonresident outsourcing facilities.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Kansas is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

K.S.A. 65-4116(a) requires annual Board of Pharmacy registration for anyone who manufactures, distributes or dispenses controlled substances, but subsection (c) lists persons who need not register, including any person licensed by the State Board of Healing Arts, dentists, veterinarians and mid-level practitioners. Subsection (d) adds that licensure by the Board of Healing Arts constitutes compliance with the Uniform Controlled Substances Act registration requirement for the practitioner's place of professional practice. A Kansas license plus DEA registration is therefore what is required.

Mid-level practitioners (APRNs, PAs) are expressly exempt under 65-4116(c)(8). K-TRACS (PDMP) rules not researched here.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

The Kansas Prescription Monitoring Program Act (K.S.A. 65-1681 to 65-1694) sets up K-TRACS and dispenser reporting, but no section read contains a general requirement for prescribers to query before prescribing. The PDMP TTAC list and Kansas profile cite only the 'Kansas Medicaid PDMP Policy (KanCare)' as a prescriber mandate. Federal law (42 U.S.C. 1396w-3a, effective October 1, 2021) requires state Medicaid plans to make covered Medicaid providers check a PDMP before prescribing a Schedule II controlled substance, with states free to add Schedules III-IV; the KanCare policy text was not reviewed, so whether it reaches Schedule III is unknown. K-TRACS is run by the Kansas Board of Pharmacy.

Conditional = Medicaid (KanCare) only, per PDMP TTAC; the KanCare policy itself was not opened (pharmacy.ks.gov/k-tracs blocked automated access). State statute review found no general mandate. Check the Kansas Board of Pharmacy K-TRACS page for any newer requirement.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

K.A.R. 100-21-1 defines a dispensing physician as one who keeps drugs and fills his or her own prescriptions for patients. K.A.R. 100-21-2 requires typed labels with physician name, address and phone, patient name, prescription number, date, directions, expiration and drug name and strength; K.A.R. 100-21-3 requires child-resistant, light-resistant containers. No registration requirement was found in these rules; a vendor summary also reports none. Dispensed controlled substances are reported to K-TRACS.

Rules date from 1981 and remain in effect; K.A.R. 100-21-4 and -5 were not reviewed.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Kansas regulations state that the same laws and regulations that apply to prescribing drugs, including controlled substances, in person apply to prescribing by telemedicine (K.A.R. 100-77-3). A Kansas license is required, with a limited statutory route for out-of-state physicians practicing telemedicine, who must assess the patient and document the medical indication for any prescription (K.S.A. 65-28,135 as cited by CCHP). No Kansas telehealth-specific Schedule III limit was found. IMLC: member.

Scope of the out-of-state physician provision was not confirmed; check with the Kansas Board of Healing Arts.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Kansas State Board of Nursing's practice resources (checked 2026-09-23) offer a general RN/LPN scope-of-practice decision tree but no statement on cosmetic injectables, and the Board of Healing Arts' regulations (K.A.R. Agency 100) contain a light-based device rule but no cosmetic-injection rule.

Check with the Kansas State Board of Nursing and Board of Healing Arts.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Kansas State Board of Nursing's IV therapy page concerns LPN IV therapy certification; no guidance on IV hydration businesses, individual exams, standing orders or mobile services was located on 2026-09-23.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide rates Kansas 'Moderate', citing K.S.A. 65-2803, 65-2837 and 65-2867 and cases including Early Detection Center v. Wilson; MedPath Compliance (reviewed 2026-06-20) lists Kansas as 'Yes' based on case law. Board of Healing Arts regulation K.A.R. 100-78-1 (effective 2020) sets annual expiry for business entity certificates of authorization issued by the Board.

Which entities need the certificate, and ownership limits, were not confirmed.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

K.A.R. 100-27-1 says only a licensed physician may authorize use of a light-based medical device and may delegate it to other persons. For Class III or IV devices the physician must be physically present or 'immediately available' (able to reach the treatment location within five minutes) under a written protocol; other light-based devices may be used with the physician immediately available or present under a protocol. The protocol must verify the operator's competence, cover informed consent, name the physician and contact details, restrict treatment locations, set operating parameters, require records reviewed by the physician within 14 days and bar further delegation.

Last amended 2006 (over two years old) but current per LII on 2026-09-23.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Kansas was not among them, but this research did not confirm its statutes. Kansas's CLIA state agency is Kansas Dept. of Health & Environment, CLIA Laboratory Certification (kdhe.clia2@ks.gov, 785-296-3811); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Kansas's rule. Kansas's lab regulator (CLIA state agency) is Kansas Dept. of Health & Environment, CLIA Laboratory Certification (kdhe.clia2@ks.gov, 785-296-3811). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) describes Kansas as low-restriction; not confirmed against state law. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

K.S.A. 76-835 et seq. (L. 2013, ch. 114) directs the University of Kansas Medical Center to run the Midwest Stem Cell Therapy Center. Its funds and facilities must be dedicated to treatments and research with adult, cord blood and related non-embryonic stem cells, not embryonic stem cells or fetal tissue (K.S.A. 76-839). The statute does not regulate private clinics' use of stem cell, birth-tissue or exosome products, so those remain governed by FDA rules and general medical-practice law. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Counted as 'yes' because it is stem-cell-specific, but there are no clinic notice, consent or permission rules.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Kansas does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.